Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heavy metal containing doai
Reexamination Certificate
2011-07-12
2011-07-12
Kosack, Joseph R (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heavy metal containing doai
C514S184000, C544S225000, C546S002000, C548S101000, C556S136000, C556S137000
Reexamination Certificate
active
07977381
ABSTRACT:
The subject invention concerns platinum complexes that exhibit antitumor cell and/or antiparasitic activity. The subject invention also concerns the use of platinum complexes of the invention to treat oncological and inflammatory disorders. The platinum complexes of the invention can also be used to treat or prevent infection by a virus or a bacterial or parasitic organism in vivo or in vitro.
REFERENCES:
patent: 3904663 (1975-09-01), Tobe et al.
patent: 4177263 (1979-12-01), Rosenberg et al.
patent: 5849790 (1998-12-01), Palmer et al.
patent: 5998648 (1999-12-01), Sohn et al.
patent: 7238372 (2007-07-01), Turkson et al.
patent: 7754684 (2010-07-01), Stewart et al.
patent: 2002/0035243 (2002-03-01), Imfeld et al.
patent: 2002/0120100 (2002-08-01), Bonny
patent: 2003/0032594 (2003-02-01), Bonny
patent: 2004/0175369 (2004-09-01), Yu et al.
patent: 2005/0074502 (2005-04-01), Turkson et al.
patent: 2005/0080131 (2005-04-01), Kay et al.
patent: 2009/0214626 (2009-08-01), Kay et al.
patent: 2010/0190180 (2010-07-01), Kay
patent: 0328274 (1989-08-01), None
patent: 0812852 (1997-12-01), None
patent: H08-176175 (1996-07-01), None
patent: WO 96/26949 (1996-09-01), None
patent: WO 2005/016946 (2005-02-01), None
patent: WO 2005/023824 (2005-03-01), None
PLATINOL-AQ (cisplatin injection) package insert. Revised Apr. 2006.
www.cancer.gov/cancertopics/alphalist accessed Jul. 15, 2008.
Cleare et al. “Antitumor platinum compounds Relation between structure and activity” Platinum Metals Review (1973), 17(1), 2-13.
Akira, S. “Roles of STAT3 Defined by Tissue-Specific Gene Targeting”,Oncogene, 2000, pp. 2607-2611, vol. 19.
Ardizzoni, A. et al. “The Combination of Etoposide and Cisplatin in Non-Small-Cell Lung Cancer (NSCLC)”,Ann. Oncol., 1999, pp. S13-S17, vol. 10.
Bowman, T. et al. “STATs in Oncogenesis”,Oncogene, 2000, pp. 2474-2488, vol. 19.
Bowman, T. et al. “Stat3-Mediated Myc Expression is Required for Src Transformation and PDGF-Induced Mitogenesis”,Proc Natl. Acad. Sci. USA, 2000, pp. 7319-7324, vol. 98, No. 3.
Bromberg, J. F. et al. “Transcriptionally Active Stat1 is Required for the Antiproliferative Effects of Both Interferon Alpha and Interferon Gamma”,Proc. Natl. Acad. Sci. USA, 1996, pp. 7673-7678, vol. 93.
Bromberg, J. F. et al. “Stat3 Activation is Required for Cellular Transformation by V-src”, Mol. Cell. Biol., 1998, pp. 2553-2558, vol. 18, No. 5.
Bromberg, J. F. et al. “Stat3 as an Oncogene”,Cell, 1999, pp. 295-303, vol. 98.
Catlett-Falcone, R. et al. “Constitutive Activation of Stat3 Signaling Confers Resistance to Apoptosis in Human U266 Myeloma Cells”,Immunity, 1999, pp. 105-115, vol. 10.
Catlett-Falcone, R. et al. “STAT Proteins as Novel Targets for Cancer Therapy”,Curr. Opin. Oncol., 1999, pp. 490-496, vol. 11.
Chernyaev et al. Zhurnal Neorganicheskoi Khimii, 1966, pp. 1365-1373, vol. 11, XP009041845.
Coffer, P. J. et al. “The Role of STATs in Myeloid Differentiation and Leukemia”,Oncogene, 2000, pp. 2511-2522, vol. 19.
Cuny, G.D. et al. “Photoactivated Virucidal Properties of Tridentate 2,2′-Dihydroxy Azobenzene and 2-Salicylideneaminophenol Platinum Pyridine Complexes”,Bioorganic&Medicinal Chemistry Letters, 1999, pp. 237-240, vol. 9.
Darnell, J. E., Jr. et al. “Jak-STAT Pathways and Transcriptional Activation in Response to IFNs and Other Extracellular Signaling Proteins”,Science, 1994, pp. 1415-1421, vol. 264, No. 5164.
Darnell, J. E., Jr. “STATs and Gene Regulation”,Science, 1997, pp. 1630-1635, vol. 277.
Epling-Burnette, P. K. et al. “Inhibition of STAT3 Signaling Leads to Apoptosis of Leukemic Large Granular Lymphocytes and Decreased Mcl-1 Expression”,J. Clin. Invest, 2001, pp. 351-361, vol. 107, No. 3.
Fukada, T. et al. “Two Signals are Necessary for Cell Proliferation Induced by a Cytokine Receptor gp130: Involvement of STAT3 in Anti-Apoptosis”,Immunity, 1996, pp. 449-460, vol. 5.
Garcia, R. et al. “Constitutive Activation of Stat3 in Fibroblasts Transformed by Diverse Oncoproteins and in Breast Carcinoma Cells”,Cell Growth Diff., 1997, pp. 1267-1276, vol. 8.
Garcia, R. et al. “Activation of STAT Transcription Factors in Oncogenic Tyrosine Kinase Signaling”,J. Biomed. Sci., 1998, pp. 79-85, vol. 5.
Garcia, R. et al. “Constitutive Activation of Stat3 by the Src and JAK Tyrosine Kinases Participates in Growth Regulation of Human Breast Carcinoma Cells”,Oncogene, 2001, pp. 2499-2513, vol. 20.
Gouilleux, F. et al. “Prolactin and Interleukin-2 Receptors in T Lymphocytes Signal Through a MGF-STAT5-like Transcription Factor”,Endocrinology, 1995, pp. 5700-5708, vol. 136, No. 12.
Grandis, J. R. et al. “Requirement of Stat3 but Not Stat1 Activation for Epidermal Growth Factor Receptor-Mediated Cell Growth In Vitro”,J. Clin. Invest., 1998, pp. 1385-1392, vol. 102, No. 7.
Grandis, J. R. et al. “Constitutive Activation of Stat3 Signaling Abrogates Apoptosis in Squamous Cell CarcinogenesisIn Vivo”, Proc. Natl. Acad. Sci. USA, 2000, pp. 4227-4232, vol. 97, No. 8.
Grandis, J. R. et al. “Epidermal Growth Factor Receptor—Mediated Stat3 Signaling Blocks Apoptosis in Head and Neck Cancer”,Laryngoscope, 2000, pp. 868-874, vol. 110.
Hirano, T. et al. “Roles of STAT3 in Mediating the Cell Growth, Differentiation and Survival Signals Relayed Through the IL-6 Family of Cytokine Receptors”,Oncogene, 2000, pp. 2548-2556, vol. 19.
Horiguchi, A. et al. “STAT3, but Not ERKs, Mediates the IL-6-Induced Proliferation of Renal Cancer Cells, ACHN and 769P”,Kidney Int, 2002, pp. 926-938, vol. 61.
Johnson, P. J. et al. “Overexpressed pp60c-srcCan Induce Focus Formation Without Complete Transformation of NIH 3T3 Cells”,Mol. Cell. Biol., 1985, pp. 1073-1083, vol. 5, No. 5.
Kotenko, S. V. et al. “Jak-Stat Signal Transduction Pathway Through the Eyes of Cytokine Class II Receptor Complexes”,Oncogene, 2000, pp. 2557-2565, vol. 19.
Kunisada, K. et al. “Activation of gp130 Transduces Hypertrophic Signals Via STAT3 in Cardiac Myocytes”,Circulation, 1998, pp. 346-352, vol. 98.
Le Postollec “Spectres de vibration et struture de composes de coordination nitres du platine IV”Journal de La Chimie Physique et de Physico-Chime Biologique, 1965, pp. 67-72, vol. 62, XP009041900.
Lin, T. S. et al. “STAT Signaling in the Pathogenesis and Treatment of Leukemias”,Oncogene, 2000, pp. 2496-2504, vol. 19.
Muraveiskaya et al. Zhurnal Neorganicheskoi Khimii, 1971, pp. 1643-1649, vol. 16, XP009041849.
Muravenskaya et al. Koordinatsionnaya Khimiya, 1975, pp. 779-790, vol. 1, XP009041867.
Nielsen, M. et al. “Constitutive Activation of a Slowly Migrating Isoform of Stat3 in Mycosis Fungoides: Tyrphostin AG490 Inhibits Stat3 Activation and Growth of Mycosis Fungoides Tumor Cell Lines”,Proc. Natl. Acad. Sci. USA, 1997, pp. 6764-6769, vol. 94.
Nielsen, M. et al. “Inhibition of Constitutively Activated Stat3 Correlates with Altered Bcl-2/Bax Expression and Induction of Apoptosis in Mycosis Fungoides Tumor Cells”,Leukemia, 1999, pp. 735-738, vol. 13.
Nitiss, J. L. “A Copper Connection to the Uptake of Platinum Anticancer Drugs”,Proc. Natl. Acad. Sci. USA, 2002, pp. 13963-13965, vol. 99, No. 22.
Persons, D. L. et al. “Cisplatin-Induced Activation of Mitogen-Activated Protein Kinases in Ovarian Carcinoma Cells: Inhibition of Extracellular Signal-Regulated Kinase Activity Increases Sensitivity to Cisplatin”,Clin. Cancer Res., 1999, pp. 1007-1014, vol. 5.
Rudyi et al. Koordinatsionnaya Khimiya, 1975, p. 1572, vol. 1, XP009041868.
Samatov et al. Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya, 1974, pp. 2142-2144, XP009041871.
Samatov et al. Izvestiya Akademii Nauk SSSR Seriya Khimicheskaya, 1974, pp. 1467-1472, No. 9, XP009041872.
Sanchez-Perez, I.
Kay Heidi
Palmer Jay W.
Sebti Said M.
Stanko Joseph A.
Kosack Joseph R
Saliwanchik Lloyd & Eisenschenk
University of South Florida
LandOfFree
Platinum complexes and methods for inhibiting tumor cell... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Platinum complexes and methods for inhibiting tumor cell..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Platinum complexes and methods for inhibiting tumor cell... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2635580